ESTRO 2023 - Abstract Book

S982

Digital Posters

ESTRO 2023

P. Alexidis 1 , E. Kamperis 1 , V. Giannouzakos 1 , M. Topalidou 2 , G. Mpallas 2 , V. Mentesidou 2 , O. Kimoundri 2 , C. Kodona 2 , K. Chatzioannou 2 1 General Hospital Papageorgiou, Radiation Therapy, Thessaloniki, Greece; 2 General Hospital Papageorgiou, Radiation Therapy , Thessaloniki, Greece Purpose or Objective To investigate factors resulting to dysphagia (primary outcome) and treatment delays (secondary outcome) in patients receiving concurrent radiation therapy and chemotherapy for malignancies arising from the oral cavity or oropharynx. Materials and Methods Retrospective analysis of the patient records who received RT to the primary and bilateral neck lymph nodes concurrently with chemotherapy, was carried out. Logistic regression models were used to investigate predictive factors of dysphagia grade ≥ 2 or prolongation of total treatment duration ≥ 7 days. Results 160 patients were included in the study. Mean age was 63.31 (SD= 8.24). The mean treatment duration was 6,7 weeks. 76 (47.5%) developed dysphagia grade ≥ 2, and 32 (20%) experienced treatment prolongation ≥ 7 days. The analysis showed that dysphagia grade ≥ 2 was associated with mean dose to the constrictor muscles > 40.6 Gy (p<0.001, OR = 11.58, 95% CI [4.84 – 27.71]) and to the anatomical volume in the primary that received ≥ 60 Gy ( ≥ 118.75 cc, p<0.001, (OR = 8.43, 95% CI [3.51 – 20.26]). Elderly patients (p=0.007, OR=1.079, 95% CI [1.021-1.140]) or those that developed dysphagia grade ≥ 2 (p=0.005, OR=4.02, 95% CI [1.53-10.53]) were more likely to experience treatment prolongation ≥ 7 days.

Conclusion In patients receiving bilateral neck irradiation concurrently with chemotherapy for oral cavity or oropharyngeal cancer, constrictors mean dose and the volume in the primary site receiving ≥ 60 Gy should be kept below 40.6 Gy and 118.75 cc respectively whenever possible. Patients that are more likely to experience treatment prolongation ≥ 7 days are elderly patients or those that are considered at high risk for dysphagia. Close monitoring during the course of treatment for nutritional support and pain management is of great significance.

PO-1226 analysis of the aMMP-8 level in patients with head and neck cancer with radiation mucositis

D. Karacetin 1 , M. Keskin 2 , E. Brandt 3 , T. Sorsa 4